Search
![](https://static.wixstatic.com/media/nsplsh_6567543378744475394451~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/nsplsh_6567543378744475394451~mv2.jpg)
![USFDA Guidance: Considerations for the Use of Human-and Animal-Derived Materials & Recognition and Use of a Standard for Uniform Blood & Blood Component Container Labels](https://static.wixstatic.com/media/nsplsh_6567543378744475394451~mv2.jpg/v1/fill/w_399,h_300,fp_0.50_0.50,q_90,enc_auto/nsplsh_6567543378744475394451~mv2.jpg)
Sharan Murugan
- May 1
- 2 min
USFDA Guidance: Considerations for the Use of Human-and Animal-Derived Materials & Recognition and Use of a Standard for Uniform Blood & Blood Component Container Labels
Yesterday (30 April 2024), the FDA released a draft guidance for the industry titled "Considerations for the Use of Human-and...
17 views0 comments
![](https://static.wixstatic.com/media/nsplsh_97d9977b3f474d299322aa4a6c1c0bf3~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/nsplsh_97d9977b3f474d299322aa4a6c1c0bf3~mv2.jpg)
![USFDA Guidance: Content and Format of Composition Statements in NDAs and ANDAs and Corresponding Statement of Ingredients in Labeling](https://static.wixstatic.com/media/nsplsh_97d9977b3f474d299322aa4a6c1c0bf3~mv2.jpg/v1/fill/w_399,h_300,fp_0.50_0.50,q_90,enc_auto/nsplsh_97d9977b3f474d299322aa4a6c1c0bf3~mv2.jpg)
Sharan Murugan
- Apr 27
- 2 min
USFDA Guidance: Content and Format of Composition Statements in NDAs and ANDAs and Corresponding Statement of Ingredients in Labeling
Today (29 April 2024), FDA released a new draft guidance for the industry titled "Content and Format of Composition Statement and...
28 views0 comments
![](https://static.wixstatic.com/media/nsplsh_a7006c204eb84137a9479de050c3b977~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/nsplsh_a7006c204eb84137a9479de050c3b977~mv2.jpg)
![USFDA Guidance: Cancer Clinical Trial Eligibility Criterias](https://static.wixstatic.com/media/nsplsh_a7006c204eb84137a9479de050c3b977~mv2.jpg/v1/fill/w_399,h_300,fp_0.50_0.50,q_90,enc_auto/nsplsh_a7006c204eb84137a9479de050c3b977~mv2.jpg)
Sharan Murugan
- Apr 27
- 2 min
USFDA Guidance: Cancer Clinical Trial Eligibility Criterias
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for...
7 views0 comments
![](https://static.wixstatic.com/media/nsplsh_2d6171385274416a546549~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/nsplsh_2d6171385274416a546549~mv2.jpg)
![USFDA Guidance: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Q&A](https://static.wixstatic.com/media/nsplsh_2d6171385274416a546549~mv2.jpg/v1/fill/w_399,h_300,fp_0.50_0.50,q_90,enc_auto/nsplsh_2d6171385274416a546549~mv2.jpg)
Sharan Murugan
- Apr 27
- 2 min
USFDA Guidance: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Q&A
On 24 April 2026 (Wednesday) the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research released a...
14 views0 comments
![](https://static.wixstatic.com/media/6516fb_aa86e84c188f43038c8283362a964202~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/6516fb_aa86e84c188f43038c8283362a964202~mv2.jpg)
![EMA: Guidance on the Anonymisation of PPD & Assessment of CCI during the preparation of RMPs](https://static.wixstatic.com/media/6516fb_aa86e84c188f43038c8283362a964202~mv2.jpg/v1/fill/w_399,h_300,fp_0.50_0.50,q_90,enc_auto/6516fb_aa86e84c188f43038c8283362a964202~mv2.jpg)
Sharan Murugan
- Apr 27
- 2 min
EMA: Guidance on the Anonymisation of PPD & Assessment of CCI during the preparation of RMPs
The European Medicines Agency (EMA) yesterday (26 April, 2024) released an updated guidance on the "Anonymisation of protected personal...
25 views0 comments